Robert Lisak

Ocrevus a Year After Approval: Views of Some MS Experts

A year after U.S. regulators approved Genentech’sĀ Ocrevus (ocrelizumab)Ā as the first treatment for both the relapsing and progressive forms of multiple sclerosis, a prominent neurologist involved in the Phase 3 clinical trials that led to its authorization says it has been beneficial for some MS patients. But itā€™s simply…

#CMSC17 – Ocrevus, Progressive MS and Other Research Highlights: An Interview with CMSC’s Robert Lisak

The recent annual meeting of theĀ Consortium of Multiple Sclerosis Centers (CMSC)Ā brought researchers and healthcare professionals to New Orleans to discuss advances ā€” and obstacles to advances ā€” in multiple sclerosis (MS) research. Clinical trials, preclinical studies, basic research, and health interventions were amongĀ the May meeting’s focus. Multiple Sclerosis News…

Are Ocrevus and Rituxan Similar? Neurologists Respond to Patients’ Concerns

While manyĀ multiple sclerosis patients celebrated the recent approval of Ocrevus (ocrelizumab), others argued that the drug is largelyĀ a rebranded version ofĀ rituximab. Rituximab ā€” sold as Rituxan for indications like non-Hodgkin’s lymphoma,Ā chronic lymphocytic leukemia, andĀ rheumatoid arthritis ā€” is used off-label to treat relapsing MS. In online forums and social media,…

Ocrevus Holds Promise, But Needs to Prove Itself in ‘Long Term,’ Says Dr. Robert Lisak with CMSC

Interest inĀ  Ocrevus (ocrelizumab), the first FDA-approved treatment for bothĀ relapsing and primary progressive multiple sclerosis, isĀ running high among patients and the organization representing them ā€” as, arguably, are expectations ofĀ its use. But how do physicians involved in MS care view the newcomer? Dr. Robert Lisak (Photo courtesy…